Navigation Links
Sepsis risk increased due to the absence of one key enzyme

The presence of caspase-12, touted as the wonder enzyme in sepsis increases the bodys vulnerability to bacterial infection and septic shock while a deficiency confers strong resistance to sepsis. //

This enzyme appears to modulate inflammation and innate immunity in humans.

"The results of the study make clear that caspase-12 plays a critical role in the elimination of bacterial pathogens, and that a deficiency allows systemic and abdominal infections to be better resolved. It's known that the presence of caspase-12 as a full length protein occurs in a small percentage of people of African descent. As a result, some of these individuals are far more susceptible to severe sepsis and have a significantly increased risk of dying from it," said Richard Ulevitch, chair of the Scripps Research Immunology Department and an author of the paper. The study appears in Nature.

The new study showed that caspase-12 deficient mice were resistant to peritonitis and septic shock and were able to clear pathogenic bacteria more efficiently than mice with the enzyme.

Ulevitch said, "Without the experimental model of peritonitis perfected by John Mathison from Scripps Research, we would not have been able to differentiate between the two mouse phenotypes. Because of his work, we were able to use a surgically implanted stent in the colon that allowed a gradual occurrence of sepsis and easy identification. The resulting beneficial effect of cytokine hyper-production runs contrary to some of the current thinking in sepsis research. The general thinking is that this initial cytokine 'storm' is harmful, and that belief has been the basis of a number of unsuccessful clinical studies. In our study, cells containing caspase-12 appear to weaken the activity of caspase-1 that is normally essential for bacterial clearance and sepsis survival."

While caspase-12 was previously thought to be a key mediator of endoplasmic reticulum apoptosis, the new st udy found that the presence or absence of caspase-12 had no effect on apoptotic sensitivity whatsoever.

It could have great and significant contribution is the therapeutic approaches to injuries.


Related medicine news :

1. Sepsis treatment functions best in difficult cases
2. Sepsis Death Reported With Mifepristone – FDA Issues Warnin
3. Researchers identify the early makers of Neonatal Sepsis
4. Drexel Research in Cytokines Could Treat Sepsis
5. Mortality increased in Sporting enthusiasts!
6. Strokes increased during squatting
7. Asthmatics at increased risk of lung cancer
8. Renal problem increased
9. Risk of hemorrhagic stroke increased in smoking individuals
10. Heart attack risk increased by depression
11. Breast cancer risk not increased by acrylamide
Post Your Comments:

(Date:12/1/2015)... ... 2015 , ... The Multiple System Atrophy Coalition has announced the launch of ... (MSA) research, timed today to coincide with Giving Tuesday 2015, a global day of ... to work and be productive, to do simple daily activities like walking to the ...
(Date:12/1/2015)... ME (PRWEB) , ... December 01, 2015 , ... Royal ... reports a new study that found post-menopausal women who took the nutritional supplement creatine, ... than women who trained but did not take creatine. , The report is part ...
(Date:12/1/2015)... Fla. (PRWEB) , ... December 01, 2015 , ... ... number of leadless pacemakers in the U.S. and is the only hospital in ... from the largest clinical data presentation of transcatheter pacing patients were revealed recently ...
(Date:12/1/2015)... ... December 01, 2015 , ... December 1, ... expansion of the company’s growing product line of food safety and seafood fraud ... Sockeye (Oncorhynchus nerka) – allow InstantLabs to offer fast, reliable species identification for ...
(Date:12/1/2015)... ... December 01, 2015 , ... Diabetic ... United States. Podiatrists are well aware that psychology-based patient non-compliance (disobedience of a ... catastrophic contributors to diseases of the diabetic foot. The American Board of ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... 1, 2015   MabVax Therapeutics Holdings, Inc . ... it has filed an Investigational New Drug Application (IND) ... the Company,s lead fully human antibody product HuMab 5B1 ... plans to initiate the Phase I clinical trial early ... --> The planned Phase I trial will evaluate ...
(Date:12/1/2015)... , Dec. 1, 2015   Craneware, Inc ... cycle solutions, today announced the company will showcase ... ChargeLink ® solution at the American ... Clinical Meeting . The new features are focused ... of monitoring and managing enterprise-wide pharmacy charges to ...
(Date:12/1/2015)... , Dec. 01, 2015 ... of the "Medical Alert Systems/Personal Emergency Response ... by Geography - Global Forecas" report to ... announced the addition of the "Medical Alert ... by End-User and by Geography - Global Forecas" ...
Breaking Medicine Technology: